Nationwide epidemiological survey of autoimmune pancreatitis in Japan in 2021
Journal of Gastroenterology · 2026-10 · 61 (10) · 1502-1511
DOI: 10.1007/s00535-026-02438-w ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Gastroenterology, online erschienen am 19.05.2026. Verfasst von Atsushi Masamune und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai, 980-8574, Japan. atsushi.masamune.d2@…. Hauptthemen laut MEDLINE: Autoimmune Pancreatitis. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Health, Labour and Welfare, Japan Pancreas Society.
Abstract (Originalsprache)
Background
To update the clinic-epidemiological features of autoimmune pancreatitis (AIP) in Japan, we conducted the fifth nationwide survey.
Methods
We performed a two-stage survey of patients with AIP who were treated at selected hospitals in 2021. The first-stage survey estimated the total number of patients with AIP, and the second-stage survey analyzed detailed clinical characteristics.
Results
The estimated number of patients with AIP in 2021 was 16,750 (prevalence, 13.3 per 100,000 persons), representing a 25% increase from 2016. The number of newly diagnosed cases was 4210 (annual incidence, 3.4 per 100,000 persons). Clinical data were available for 2833 patients. The male-to-female ratio was 3.32:1, and the mean age in 2021 and the mean age at AIP diagnosis were 71.2 and 66.3 years, respectively. At diagnosis, 58.6% of patients were symptomatic, approximately half of whom presented with jaundice. Other organ involvement was observed in 67.8% of patients, most commonly sclerosing cholangitis. Histopathological examination was performed in 84.1% of cases, predominantly using endoscopic ultrasonography-guided tissue acquisition. Initial glucocorticoid therapy was administered to 84.2% of patients, and 93.8% received maintenance therapy. Kaplan–Meier analysis demonstrated a cumulative relapse incidence of 12.5%, 20.7%, 36.0%, 44.0%, 53.3%, and 68.9% at 3, 5, 10, 15, 20, and 25 years, respectively. Long-term overall survival was favorable; however, malignancies accounted for 40% of deaths.
Conclusions
This nationwide survey updates the epidemiological and clinical characteristics of AIP in Japan. Patient numbers continue to rise, and the high cumulative risk of relapse underscores the need for second-line therapies beyond glucocorticoids.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Gastroenterology, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai, 980-8574, Japan. atsushi.masamune.d2@tohoku.ac.jp.
- Division of Gastroenterology, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai, 980-8574, Japan.
- Osaka Gyoumeikan Hospital, Osaka, Japan.
Förderung
- Ministry of Health, Labour and Welfare
- Japan Pancreas Society
Zitieren
APA
Masamune, A., Sano, T., Takikawa, T., Matsumoto, R., Hamada, S., Abe, T., Tanaka, Y., Takeyama, Y., Kikuta, K., & Japan Pancreatitis Study Group (2026). Nationwide epidemiological survey of autoimmune pancreatitis in Japan in 2021. Journal of Gastroenterology, 61(10), 1502-1511. https://doi.org/10.1007/s00535-026-02438-w
Vancouver
Masamune A, Sano T, Takikawa T, Matsumoto R, Hamada S, Abe T, et al. Nationwide epidemiological survey of autoimmune pancreatitis in Japan in 2021. Journal of Gastroenterology. 2026;61(10):1502-1511. doi:10.1007/s00535-026-02438-w
BibTeX
@article{Masamune2026,
author = {Masamune, Atsushi and Sano, Takanori and Takikawa, Tetsuya and Matsumoto, Ryotaro and Hamada, Shin and Abe, Toshiaki and Tanaka, Yuichi and Takeyama, Yoshifumi and Kikuta, Kazuhiro and Japan Pancreatitis Study Group, Japan Pancreatitis Study Group},
title = {Nationwide epidemiological survey of autoimmune pancreatitis in Japan in 2021},
journal = {Journal of Gastroenterology},
year = {2026},
volume = {61},
number = {10},
pages = {1502--1511},
doi = {10.1007/s00535-026-02438-w}
}
EUVIMED